InsidersTradesSigma
HLB테라퓨틱스 Stock: price and management transactions · South Korea · DART (FSS)
Follow the HLB테라퓨틱스 stock price and the full directors' dealings record of the company, a listed issuer based in South Korea. Shares are listed on KR KR, under the authority of DART (FSS). Operating in the Health Care sector, HLB테라퓨틱스 has recorded 7 reports. Market capitalisation: €196.6bn. The latest transaction was filed on 2 July 2026 (Other). Among the most active insiders: HLB. Every trade is openly available.
7
Insider Decl.
0
Thresholds
€1m
4 ops.
Buy Volume
·
0 ops.
Sell Volume
16Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 24,143 of 25,750 companies
17.6
score / 100
Value19
Quality17
FCF yld-9.4%
Earn yld-4.8%
EV/EBITDA·
ROE-5.4%
Gross mgn15%
Net mgn-13%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 2 July 2026
Declarations7 total
7 of 7 declarations
About HLB테라퓨틱스
HLB Therapeutics is a company focused on the healthcare and pharmaceutical sector, listed on the XKRX market. It specializes in the development of innovative treatments and therapeutic solutions.